INKT - MiNK Therapeutics to Participate at Upcoming Investor Conferences
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:
- HC Wainwright 24th Annual Global Investment Conference
Fireside chat webcast will be available beginning at 7:00 AM ET on September 12 th . Registration available at: https://journey.ct.events/view/16e5cc45-7c5a-4f7d-8de1-d0c1b519dfa8
- Baird 2022 Global Healthcare Conference
Fireside chat will be held at 1:25 PM ET on September 14 th . The conference will take place at the InterContinental New York Barclay.
A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations .
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com